DRUG · Mapped RxNorm record
Dapagliflozin
Normalized identity: dapagliflozinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
NCT02653482
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Dapagliflozin matching placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedDapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
DapagliflozinDRUG · verified · RxNorm: dapagliflozin
Sponsors & collaborators
Saint Luke's Health Systemlead sponsor
Mapped research locations
Kansas CityMissouri, United States2EvanstonIllinois, United States2New YorkNew York, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1ClevelandOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02653482 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.